About Invengene Private Limited
Data last updated:
Invengene Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Inventia Healthcare Limited. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 02 August 2023.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U21002MH2023PTC407959. Its GSTIN is 27AAHCI2465D1ZO (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹1.51 Cr. It is led by directors including Ankur Janak Shah (Whole-Time Director) and Vaibhavi Ankur Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹11.75 Cr. For the same year it recorded a net loss of ₹16.49 Cr (net margin -140.3%) and EBITDA of -₹13.09 Cr (EBITDA margin -111.4%).
The company has about 35 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Invengene. As per MCA filings, the company has open charges of ₹25 Cr on record.
For more details, the company can be reached via its website invengene.com.
Company details
CIN history
Invengene has one previous CIN (Corporate Identification Number): U21002MH2023PLC407959. The current CIN is U21002MH2023PTC407959, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U21002MH2023PTC407959 | Current |
| U21002MH2023PLC407959 | Previous |
Contact details
Invengene Private Limited's registered office is in Mumbai, Maharashtra. Its website is invengene.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressUnit No. 704 7th Floor Solaris One Premises Co – Operative Society Limited, N. S. Phadke Marg, Mumbai, Maharashtra, India – 400069
- IndustryHealthcare, Preventive Health Supplements
To see the full contact details of Invengene Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Invengene operates one associated brand: Invengene. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides R&D, manufacturing, and commercialization services for pharmaceuticals worldwide. | invengene.com |
Financials of Invengene Private Limited
FY 2025 filings availableInvengene Private Limited reported revenue of ₹11.75 Cr for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | ||
| Other Income | ||
| Total Revenue | ||
| Cost of Materials Consumed | ||
| Employee Benefit Expense | ||
| Finance Costs | ||
| Depreciation and Amortisation | ||
| Other Expenses | ||
| Total Expenses | ||
| EBITDA | -₹13.09 Cr | |
| Profit Before Tax | ||
| Tax Expense | ||
| Net Profit (PAT) | -₹16.49 Cr | |
| Balance Sheet | ||
| Share Capital | ||
| Reserves and Surplus | ||
| Net Worth (Total Equity) | ||
| Long-term Borrowings | ||
| Short-term Borrowings | ||
| Trade Payables | ||
| Total Liabilities | ||
| Fixed Assets | ||
| Investments | ||
| Inventories | ||
| Trade Receivables | ||
| Cash and Bank Balance | ||
| Total Assets | ||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profitability | ||
| EBITDA Margin | -111.4% | |
| Net Profit Margin | -140.3% | |
| Return on Equity (ROE) | ||
| Return on Capital Employed (ROCE) | ||
| Return on Assets (ROA) | ||
| Liquidity and Debt | ||
| Current Ratio | ||
| Quick Ratio | ||
| Debt-to-Equity Ratio | ||
| Interest Coverage Ratio | ||
| Efficiency and Growth | ||
| Asset Turnover | ||
| Receivable Days | ||
| Payable Days | ||
| Inventory Days | ||
| Revenue Growth | ||
| Net Profit Growth | ||
To see the full financial statements and ratios of Invengene Private Limited, buy the company report.
Board of directors of Invengene Private Limited
Invengene has 6 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Janak Ramanlal Shah | Individual Subscriber | 02 Aug 2023 | 3 Years 2 Months | Current |
| Maya Janak Shah Also directs: Emjay Ventures LLP | Individual Subscriber | 02 Aug 2023 | 3 Years 2 Months | Current |
| Rajat Vishal Shah Also directs: Nature & Thought Private Limited, Nutriventia Private Limited | Individual Subscriber | 02 Aug 2023 | 3 Years 2 Months | Current |
| Ankur Janak Shah | Whole-Time Director | 02 Aug 2023 | 3 Years 2 Months | Current |
| Vishal Janak Shah Also directs: Emjay Ventures LLP, Inventia Healthcare Limited, Nature & Thought Private Limited and 1 more | Individual Subscriber | 02 Aug 2023 | 3 Years 2 Months | Current |
| Vaibhavi Ankur Shah | Whole-Time Director | 02 Aug 2023 | 3 Years 2 Months | Current |
Peer comparison
Invengene Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Contract Research), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Evolvus Technologies Private Limited | ₹12.18 Cr (FY 2025) | -12.0% | Pune, Maharashtra, India | |||
| Ortiv-Q3 Research Private Limited | ₹12.18 Cr (FY 2025) | 39.0% | Ahmedabad, Gujarat, India | |||
| Celest Pharma Labs Private Limited | ₹11.91 Cr (FY 2025) | 31.0% | Bangalore, Karnataka, India | |||
| Arvik Labs Private Limited | ₹11.81 Cr (FY 2025) | 0.0% | Hyderabad, Telangana, India | |||
| Neocell Bio-Technologies Private Limited | ₹11.75 Cr (FY 2025) | 1184.0% | Patancheru, Telangana, India | |||
| Invengene Private Limitedthis company | ₹11.75 Cr (FY 2025) | -₹16.49 Cr | -140.3% | Mumbai, Maharashtra, India | ||
| Phastar Cro Private Limited | ₹11.72 Cr (FY 2025) | 69.0% | Bangalore, Karnataka, India | |||
| Fenix Research Labs Private Limited | ₹11.62 Cr (FY 2025) | -21.0% | Hyderabad, Telangana, India | |||
| Creyon Bio India Private Limited | ₹11.5 Cr (FY 2025) | 26.0% | Bangalore, Karnataka, India | |||
| Stabicon Life Sciences Private Limited | ₹11.34 Cr (FY 2025) | 20.0% | Bengaluru, Karnataka, India | |||
| Etico Lifesciences Private Limited | ₹11.15 Cr (FY 2025) | 2.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Invengene Private Limited, buy the company report.
Auditor
Invengene Private Limited is audited by M S K C & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M S K C & Associates | FY 2024 | 001595S |
Shareholding
The shareholding of Invengene Private Limited is on record for FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Invengene Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Dec 2025 | 101209415 | Others | ₹25 Cr | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Invengene Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Invengene Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Invengene has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAHCI2465D1ZO | Maharashtra | Active | 05 Oct 2023 |
| 03AAHCI2465D1ZY | Punjab | Active | 28 Oct 2023 |
To see the full GST registrations and return filing status of Invengene Private Limited, buy the company report.
Recent activity
Invengene Private Limited has 10 board changes on record since 2023: 6 appointments and 4 cessations. The latest: Rikin Mukesh Sanghvi ceased to be Additional Director on 20 Aug 2025.
2 earlier events are in the company report.
Frequently asked questions
Invengene is an active private limited company based in Mumbai, Maharashtra, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 02 August 2023 (3+ years old) and is registered under CIN U21002MH2023PTC407959.
Invengene has 6 current directors:
- Ankur Janak Shah - Whole-Time Director
- Vaibhavi Ankur Shah - Whole-Time Director
- Janak Ramanlal Shah - Individual Subscriber
- Maya Janak Shah - Individual Subscriber
- Rajat Vishal Shah - Individual Subscriber
- Vishal Janak Shah - Individual Subscriber
The latest financial statements of Invengene on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 August 2025. Year-wise statements from FY 2024 are in the company report.
The GSTIN of Invengene is 27AAHCI2465D1ZO, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 03AAHCI2465D1ZY (Punjab).
The CIN (Corporate Identification Number) of Invengene is U21002MH2023PTC407959. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Invengene was incorporated on 02 August 2023, making it 3+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Invengene by revenue are Evolvus Technologies Private Limited, Ortiv-Q3 Research Private Limited, Celest Pharma Labs Private Limited, Arvik Labs Private Limited, Neocell Bio-Technologies Private Limited and 5 more, all in the Pharma industry (Contract Research).
Rikin Mukesh Sanghvi ceased to be Additional Director on 20 Aug 2025. Ankur Janak Shah ceased to be Director on 30 Nov 2024. Vaibhavi Ankur Shah ceased to be Director on 30 Nov 2024. Invengene has 10 board changes on record in total.
Invengene can be reached through the website invengene.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Invengene is at Unit No. 704 7th Floor Solaris One Premises Co – Operative Society Limited, N. S. Phadke Marg, Mumbai, Maharashtra, India – 400069.
Invengene operates in the healthcare industry, in the preventive health supplements segment.